Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
← catalyst calendarSponsored by Evommune, Inc. (industry) · EVMN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
120estimated
Sites
29
Countries
New Zealand, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-26 | actual | When the study began enrolling |
| Primary completion | Jul 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atoptic Dermatitis
Interventions
- Drug: EVO756
- Drug: EVO756
- Drug: EVO756
- Drug: Placebo control
Primary outcome
what the primary-completion date above is the date OFPercentage change in Eczema Area and Severity Index (EASI) from Baseline
measured Week 12
Permalink · EVMN's whole pipeline · Catalyst calendar · Every registered study · What changed